Brief: Leap Therapeutics Announces Completion Of Enrollment In Part A Of DeFianCe Study of DKN-01 For Treatment Of Colorectal Cancer Patients

Cypherpunk Technologies

12/04/2023 12:48

April 12 (Reuters) - Leap Therapeutics Inc  LPTX.O :
    * LEAP THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
PART A
OF THE DEFIANCE STUDY OF DKN-01 FOR THE TREATMENT OF COLORECTAL
CANCER PATIENTS
    * LEAP THERAPEUTICS INC - LOOK FORWARD TO INITIAL DATA FROM
STUDY
IN MID-2023

Source text for Eikon:  ID:nPnbKSGjJa 
Further company coverage:  LPTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))